Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...

The president-elect said he had an "obligation" to attack one specific late night host. A photo shared by Vice President ...

"Our study results forecast a dramatic rise in the burden from dementia in the United States over the coming decades, with ...

In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively ...

In response to increasing needs for dementia care and prevention in the aging population, a new medical practice is opening in Vienna. Sunday Health, a medical practice launched in mid-2024, ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Digital mental health platforms were supposed to expand access for the neediest patients. Researchers say that hasn’t ...

A new study finds that dementia cases are expected to double to 1 million by 2060, with African-American cases potentially ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...